Pfizer readies a monthly obesity injection from the Metsera platform

Pfizer completed its roughly $10 billion acquisition of the obesity biotech Metsera in November 2025, after a contentious bidding war in which rival Novo Nordisk tried to outbid Pfizer for the company ^[2]. The deal gives Pfizer control of Metsera's obesity pipeline, including MET-097i, a weekly-and-monthly injectable GLP-1 drug candidate that Pfizer said was "about to begin Phase 3 development" at the time the deal closed ^[2]. Metsera's pipeline also includes MET-233i, a monthly amylin analog being tested alone and in combination with MET-097i, along with an oral GLP-1 candidate still in early Phase 1 testing ^[2].

The pitch behind these programs is dosing frequency. Today's leading obesity drugs, Wegovy (semaglutide) and Zepbound (tirzepatide), are both given as weekly injections ^[1]. A drug that works with monthly dosing would ask patients to inject themselves far less often, which Pfizer and other companies see as a potential edge in a market that is rapidly filling with competitors. Industry tracking now counts more than 150 active obesity drug programs worldwide, spanning GLP-1 drugs, amylin analogs, and other mechanisms in various stages from preclinical work through Phase 3 trials ^[1].

Pfizer's CEO, Albert Bourla, described the Metsera acquisition as "a deliberate investment in the future of medicine," saying the company is "directing our resources toward one of the most impactful and high-growth therapeutic areas" ^[2]. The sources available do not provide specific Phase 2b results, a full list of more than 20 anti-obesity trials, or confirmation of the drug code PF-08653944 mentioned in some industry reporting; those details are not yet documented in the material reviewed for this story.

Other companies are also chasing less-frequent dosing. Amgen's MariTide, a monthly or less-frequent injection that combines a GLP-1 agonist with a GIP receptor antagonist, is already in Phase 3 testing and has shown roughly 20% average body-weight loss over 52 weeks in earlier-stage data, with an estimated approval timeline around May 2028, according to pipeline tracking ^[1]. That makes reduced injection frequency a competitive theme across at least two major companies, not just Pfizer.

Why it matters for patients

For people currently using or considering Wegovy, Zepbound, or other weekly GLP-1 injections, a monthly option would not necessarily mean a different kind of weight loss, but it could mean fewer injections and possibly simpler treatment routines. None of Pfizer's Metsera-derived candidates have completed the late-stage testing needed for FDA review, so it is not yet known how effective MET-097i or a similarly dosed drug will prove to be, or how its side-effect profile will compare with existing options ^[2].

It is also not yet known, based on the available sources, exactly when a monthly Pfizer obesity injection might reach pharmacies or what it might cost. Broader pipeline tracking suggests that as more companies enter this space, competition could eventually put pressure on pricing and insurance coverage, though that outcome is not guaranteed and depends on manufacturer decisions and payer policy ^[1].

What happens next

Pfizer has said MET-097i was heading into Phase 3 testing following the Metsera deal's close in November 2025 ^[2]. Phase 3 trials for obesity drugs in this class have generally taken one to several years to complete based on timelines reported for competing candidates, several of which list estimated approval dates stretching into 2028 through 2031 ^[1]. Specific trial results, enrollment numbers, or a confirmed FDA submission date for any monthly Pfizer obesity injection are not available in the sources reviewed here.